Within this group, patients diagnosed with a triple-negative tumor (N = 30, p = 0.043), but not with a Her2-positive tumor (N = 49) showed a higher risk for recurrence at high tumoral TMEM26 expression. This evidence concerns the gene ERBB2 and neoplasm.